Figure 6
From: Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis
GSK2830371 inhibits tumor growth in an orthotopic xenograft NB mouse model.
(a) The bioluminescence values of the DMSO control group and GSK2830371 treated group (25 mg/kg) were measured every week upon treatment. P < 0.001 (***) (Student’s t-test, two-tailed) was indicated. (b) Photographs of SH-SY5Y xenografted tumors and the corresponding kidney controls from DMSO control group and GSK2830371 treated group (25 mg/kg) were taken at the end of treatment (21 days). (c) SH-SY5Y-derived tumor weights from control (N = 3) and treatment groups (N = 3) are presented as the mean with SDs. P < 0.01 (**) (Student’s t-test, two-tailed) was indicated. (d) The mice bearing SH-SY5Y xenografted tumors for 4 weeks were treated with 50 mg/kg of GSK2830371 by intraperitoneal injection once. Four hours later, the mice were sacrificed and the tumors were harvested and lysed for immunoblotting with the indicated antibodies. β-Actin was detected as a loading control.
